GlassScriptPhysician profile
Charles J Loewe
NPI 1184770083
$97,739.78
in general payments reported to CMS, 2019-2025
51 companies · $8,164 in 2025
The $8,164 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,151 · 2021: $1,604 · 2022: $4,413 · 2023: $9,408 · 2024: $59K · 2025: $8,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $13K · Travel and Lodging: $8,911 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,360 · Consulting Fee: $1,180 · Honoraria: $880 · Education: $68.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,430.00 |
| Food and Beverage | $13,274.22 |
| Travel and Lodging | $8,910.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,360.00 |
| Consulting Fee | $1,180.00 |
| Honoraria | $880.00 |
| Education | $68.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $55,214.95 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,660.07 | 2019-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $11,515.81 | 2020-2025 | Ocaliva |
| Abbvie INC. | $3,296.28 | 2019-2025 | |
| Janssen Biotech, INC. | $2,784.31 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $1,484.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,285.17 | 2019-2025 | Entyvio, Gattex |
| Shionogi INC | $896.12 | 2019-2020 | |
| Boston Scientific Corporation | $829.08 | 2019-2024 | Exalt Model D, Autocap Rx, Cre Pro |
| Qol Medical, LLC | $659.82 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $648.60 | 2022-2025 | |
| Madrigal Pharmaceuticals | $607.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Biogen, INC. | $600.00 | 2019-2025 | Tysabri |
| Celgene Corporation | $538.31 | 2019-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $422.89 | 2019-2025 | Linzess |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $327.85 | 2023-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $304.70 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $289.37 | 2019-2024 | Dificid, Zinplava |
| E.R. Squibb & Sons, L.L.C. | $259.38 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $257.33 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Allergan, INC. | $246.42 | 2019-2020 | |
| Lilly USA, LLC | $241.43 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $221.00 | 2020-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $201.58 | 2022-2024 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $192.15 | 2019-2024 | Fujifilm |
| Janssen Scientific Affairs, LLC | $182.54 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $156.38 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $148.34 | 2023-2025 | Idacio, Tyenne |
| Covidien LP | $147.06 | 2019 | |
| Amgen INC. | $139.54 | 2025 | Uplizna |
| Ethicon US, LLC | $120.02 | 2022 | |
| Daiichi Sankyo INC. | $102.12 | 2021-2023 | Injectafer |
| Neuraxis, INC. | $85.56 | 2025 | |
| 3-D Matrix, INC. | $76.44 | 2024 | |
| Pharmacosmos Therapeutics INC. | $70.97 | 2022-2024 | Monoferric |
| Mallinckrodt Hospital Products INC. | $67.99 | 2024 | Terlivaz |
| Evoke Pharma, INC. | $59.00 | 2020-2021 | |
| Palette Life Sciences, INC. | $58.57 | 2022 | |
| Braintree Laboratories, INC. | $54.08 | 2021-2024 | Sutab, Suflave |
| Celltrion USA INC. | $48.67 | 2024 | Zymfentra |
| Ucb, INC. | $38.16 | 2020-2021 | |
| Vivus LLC | $35.36 | 2022 | |
| Novo Nordisk INC | $26.53 | 2025 | Wegovy |
| Organon LLC | $22.80 | 2025 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $21.88 | 2024 | Bylvay |
| Alfasigma USA, INC. | $19.26 | 2020 | |
| Pinnacle Biologics, INC | $18.49 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.30 | 2019 | |
| Shire North American Group INC | $14.94 | 2019 | |
| Cook Medical LLC | $12.18 | 2020 | |
| Biodelivery Sciences International, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Loewe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.